基于生物标志物的ABC-AF风险评分指导房颤个体化治疗:一项注册库多中心随机对照研究
本研究为多中心、注册库基础的随机对照开放标签试验,纳入3933例房颤患者,评估基于ABC-AF风险评分指导的多维治疗策略能否改善长期结局。结果显示,与常规指南指导治疗相比,ABC-AF策略组主要终点(卒中或死亡)无显著改善(HR 1.19,95%CI 0.96-1.48,P=0.12),研究因安全顾虑提前终止。
要点
- ABC-AF评分指导的治疗未显著降低卒中或死亡风险(HR 1.19,P=0.12)。
- ABC-AF组大出血、卒中、死亡及复合终点发生率与常规治疗组均无显著差异。
- 研究因CHA2DS2-VASc≥3患者死亡率升高趋势提前终止,主要终点检验效能不足。
核心结论
- 基于ABC-AF风险评分的个体化多维治疗策略未较常规指南指导治疗改善房颤患者的临床结局。
研究设计与样本
- 多中心、注册库基础、随机对照、开放标签研究,纳入成人房颤患者,意向治疗人群3933例,中位年龄73.7岁,女性33.6%,阵发性房颤51.3%,既往卒中或TIA 11.2%,口服抗凝治疗85.7%。
主要发现
- 随机化后ABC-AF策略组97.8%接受口服抗凝药,常规治疗组92.6%(P<0.0001)。
- 中位随访2.6年,主要终点(卒中或死亡)ABC-AF组175例(3.18/100患者年)vs 常规组148例(2.67/100患者年),HR 1.19(95%CI 0.96-1.48),P=0.12。
- 大出血事件152例(2.82/100患者年)vs 141例(2.61/100患者年),HR 1.08(95%CI 0.86-1.36),P=0.50。
- 卒中48例(0.87/100患者年)vs 41例(0.74/100患者年),HR 1.18(95%CI 0.78-1.79),P=0.44。
- 死亡136例(2.44/100患者年)vs 113例(2.02/100患者年),HR 1.21(95%CI 0.94-1.55),P=0.13;复合终点(卒中、死亡或大出血)277例(5.21/100患者年)vs 244例(4.55/100患者年),HR 1.14(95%CI 0.96-1.36),P=0.13。
临床怎么用
- 基于ABC-AF风险评分的个体化治疗策略未显示优于常规指南指导治疗,暂不宜常规推广。
- 研究因安全顾虑提前终止,提示在将风险分层和精准医学工具用于常规临床前需前瞻性验证。
局限性
- 研究因CHA2DS2-VASc≥3患者死亡率升高趋势的安全顾虑提前终止,主要终点检验效能不足。
- 开放标签设计可能引入偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical use of risk scores to guide treatment decisions and improve clinical outcomes has rarely been prospectively evaluated. This study aimed to evaluate whether a biomarker-based ABC-AF risk score-guided multidimensional treatment strategy improves long-term outcomes in patients with AF. METHODS: The multicenter, registry-based, randomized, controlled, open-label study enrolled adults with AF. In the ABC-AF strategy arm, the investigator was informed of each individual's ABC-AF score risks for stroke and bleeding, which were used as decision support to tailor treatment recommendations, including preference for type of direct oral anticoagulant treatment. In the standard of care arm, patient management was at the discretion of the investigator. Primary outcome was a composite of stroke or death. Secondary outcomes included stroke, death, major bleeding events, and their composite outcome. RESULTS: The intention-to-treat population comprised 3933 patients with a median age of 73.7 years; 33.6% were women, 51.3% had paroxysmal AF, 11.2% had a previous stroke or transient ischemic attack, and 85.7% had oral anticoagulant treatment. After randomization, 97.8% in the ABC-AF strategy arm and 92.6% in the standard of care arm received OACs (P<0.0001). Enrollment was prematurely terminated owing to safety concerns with a trend toward higher mortality in patients with CHA2DS2-VASc scores of ≥3, and the study was therefore underpowered for its primary objective. Over a median follow-up of 2.6 years, 175 primary events (3.18/100 patient-years [100PY]) occurred in the ABC-AF strategy and 148 (2.67/100PY) in the standard of care arm (hazard ratio [HR], 1.19 [95% CI, 0.96-1.48]; P=0.12). Major bleeding events were 152 (2.82/100PY) versus 141 (2.61/100PY; HR, 1.08 [95% CI, 0.86-1.36]; P=0.50), stroke 48 (0.87/100PY) versus 41 (0.74/100PY; HR, 1.18 [95% CI, 0.78-1.79]; P=0.44), death 136 (2.44/100PY) versus 113 (2.02/100PY; HR, 1.21 [95% CI, 0.94-1.55]; P=0.13), and rates of composite stroke, death, or major bleeding 277 (5.21/100PY) versus 244 (4.55/100PY; HR, 1.14 [95% CI, 0.96-1.36]; P=0.13). Primary outcome results were similar across ABC-AF score subgroups (interaction P=0.98). CONCLUSIONS: The individually tailored multidimensional treatment strategy, based on ABC-AF risk scores, did not improve clinical outcomes compared with usual guideline-based care in patients with AF. The results emphasize the need for prospective testing of the use of risk stratification and precision medicine tools in different clinical settings before implementation in routine care. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03753490.
引用
- Oldgren, Hijazi, Arheden, et al. Biomarker-Based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation: A Registry-Based, Multicenter, Randomized, Controlled Study. Circulation. 2025. PMID: 40884774. doi:10.1161/CIRCULATIONAHA.125.076725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。